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Killer Ig-like receptors (KIRs) control the activation of human NK cells via interactions with peptide-laden HLAs. KIR3DL1 is
a highly polymorphic inhibitory receptor that recognizes a diverse array of HLAmolecules expressing the Bw4 epitope, a groupwith
multiple polymorphisms incorporating variants within the Bw4 motif. Genetic studies suggest that KIR3DL1 variation has func-
tional significance in several disease states, including HIV infection. However, owing to differences across KIR3DL1 allotypes, HLA-
Bw4, and associated peptides, the mechanistic link with biological outcome remains unclear. In this study, we elucidated the impact
of KIR3DL1 polymorphism on peptide-laden HLA recognition. Mutational analysis revealed that KIR residues involved in water-
mediated contacts with theHLA-presented peptide influence peptide binding specificity. In particular, residue 282 (glutamate) in the
D2 domain underpins the lack of tolerance of negatively charged C-terminal peptide residues. Allotypic KIR3DL1 variants, defined
by neighboring residue 283, displayed differential sensitivities to HLA-bound peptide, including the variable HLA-B*57:01–
restricted HIV-1 Gag-derived epitope TW10. Residue 283, which has undergone positive selection during the evolution of human
KIRs, also played a central role in Bw4 subtype recognition by KIR3DL1. Collectively, our findings uncover a common molecular
regulator that controls HLA and peptide discrimination without participating directly in peptide-laden HLA interactions.
Furthermore, they provide insight into the mechanics of interaction and generate simple, easily assessed criteria for the
definition of KIR3DL1 functional groupings that will be relevant in many clinical applications, including bone marrow
transplantation. The Journal of Immunology, 2014, 192: 2875–2884.
K
iller Ig-like receptors (KIRs) are a rapidly evolving family
of transmembrane glycoproteins expressed on subsets of
T cells and NK cells in humans. Fourteen constituent
members are described, including both inhibitory and activating
receptors (1). At present, the best characterized function of KIRs
is the transmission of an inhibitory signal upon engagement of
HLA molecules.
The three Ig domain (D0, D1, D2) inhibitory receptor 3DL1
recognizes HLA-A and HLA-B molecules that express the Bw4
public epitope (2) within the a1 domain of the HLA H chain. More
than 70 allotypes of 3DL1 have been described to date, in addition
to the presence of an activating receptor variant termed 3DS1 (3).
Analysis of genetic sequence variation has led to the grouping of
3DL1 alleles into three lineages, 3DS1, *015-like, and *005-like
alleles, which appear to have been maintained through evolution via
balancing selection (4). 3DL1 polymorphism can impact allotype
expression levels, HLA recognition, and peptide sensitivity (5–9).
Based on Ab staining of peripheral blood NK cells, 3DL1 variants
were initially grouped into “high”- (e.g., *015, *001) and “low”-
(e.g., *005) expressing allotypes (6, 10). It has now become clear
that there is a spectrum of cell surface expression levels primarily
dictated by the degree of intracellular KIR retention (11). Specific
interactions with HLA molecules are also allotype-dependent (5,
8). Additionally, tetramer binding studies have uncovered a role
for allotypic diversity in peptide selectivity (9). Although some
polymorphic residues in 3DL1 have been shown to affect the
strength of the inhibitory signal after HLA engagement (e.g., the
D2 residue 238 and the transmembrane residue 320 in 3DL1*007),
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the molecular mechanisms responsible for these functional differ-
ences remain unclear (5).
Originally defined serologically, the Bw4 epitope is formed by
amino acid residues at positions 77–83 on the a1 helix of the HLA
molecule. Within the Bw4 epitope itself, there are three poly-
morphic positions (77, 80, and 81) giving rise to at least four
distinct protein sequences. Notably, the dimorphic residue at po-
sition 80 incorporates either isoleucine (Bw4 80I) or threonine
(Bw4 80T). This position was identified as a point of contact in the
recently reported 3DL1*001-HLA-B*57:01 structure, and muta-
tion of Ile to Thr at position 80 of HLA-B*57:01 reduced the
KIR–HLA interaction affinity (12). Earlier reports also provide
evidence that 3DL1 prefers HLA Bw4 molecules that express
isoleucine rather than threonine at position 80 (13, 14).
The functional consequences of KIR–HLA interactions have been
examined in genetic association studies across many disease cohorts
(15). In HIV infection, Martin et al. (16) reported that distinct KIR/
HLA combinations are beneficial. Specifically, genes encoding high
3DL1 allotypes provided greater protection from progression to
AIDS when found in combination with Bw4 80I alleles (including
HLA-B*57:01), whereas low 3DL1 variants enhanced protection
associated with the Bw4 80T allele HLA-B*27:05. One possible
interpretation of this dichotomy is that these KIR/HLA combina-
tions interact potently to deliver optimal inhibitory signals to im-
mune cells. Loss of this signal owing to HIV-induced HLA class I
downregulation, infection-related changes in peptide presentation
patterns, or other mechanisms would consequently result in greater
levels of effector cell activation. Associations based on similar KIR
groupings (high versus low) have also been found in studies of
susceptibility to HIV acquisition (17) and leukemia relapse after
allogeneic hematopoietic stem cell transplantation (Katharine Hsu,
Memorial Sloan–Kettering Cancer Center, personal communication).
Although these results highlight the role of NK cells and 3DL1 in
disease outcomes, the underlying functional mechanisms have not
been explored.
We recently described the crystal structure of 3DL1*001 in
complex with HLA-B*57:01 presenting a self-peptide (12). The
D0 domain, a previously poorly understood feature of KIR–HLA
interactions, contacted a conserved region of HLA-B*57:01 extend-
ing toward the invariant b2-microglobulin molecule, thereby acting as
an “innate” HLA binding domain. In contrast, the D1–D2 binding
face contacted the Bw4 epitope of HLA-B*57:01 and position 8 (P8)
of the bound peptide. These structural data support previous studies in
which the interaction of 3DL1 with HLA-B*27:05 was found to be
dependent on the peptide residues at P7 and P8 (18–20). The func-
tional role of peptide selectivity was further highlighted by Liberatore
et al. (21) who found that transduction with a neo-expression con-
struct rendered cells susceptible to lysis by autologous NK cells. This
effect was due to a loss of 3DL1 recognition resulting from prefer-
ential loading of a nonpermissive peptide into HLA-B*27. Such
perturbations of the HLA-bound peptide repertoire may arise natu-
rally due to changes in intracellular protein content (e.g., during in-
fection, transformation, or cellular stress) or iatrogenically due to drug-
mediated effects on peptide-binding profiles (22). Accordingly, 3DL1
recognition of a limited HLA-bound peptide repertoire provides
a mechanism for immune cell activation as a consequence of changes
in cellular processes associated with infection or transformation.
Despite clear evidence from genetic studies that Bw4 80T/80I
discrimination is fundamental to certain disease outcomes, we
do not yet fully understand the mechanisms involved at the mo-
lecular level or the role of 3DL1 polymorphism in this process. In
this study, we performed extensive binding and mutational analyses
in conjunction with structural investigations to decipher the func-
tional consequences of allelic variation at the 3DL1 locus.
Materials and Methods
Cell lines
HEK293T cells were maintained in DMEM supplemented with 10% FCS,
2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. Jurkat
cells stably expressing chimeric 3DL1-CD3z reporter constructs (8) were
maintained in RPMI 1640 medium supplemented with 10% FCS, 2 mM
L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, and 0.5 mg/ml
geneticin. Ba/F3 cells were maintained in RPMI 1640 medium supple-
mented with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml
streptomycin, and 10 ng/ml murine IL-3. RMA-S cell lines were main-
tained in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml
penicillin, 50 mg/ml streptomycin, and 0.5 mg/ml geneticin.
Crystallization and data collection
The HLA class I H chain and b2-microglobulin were refolded from inclusion
body preparations expressed in Escherichia coli and purified as detailed
previously (23). KIR3DL1*001 was expressed in HEK293S cells and purified
from the secreted fraction by nickel-affinity and size-exclusion chromatog-
raphy. Crystals were obtained at 294 K by the hanging-drop vapor-diffusion
method. The ternary complex was crystallized in conditions previously
established (12) from a reservoir solution comprising 16% PEG 3350, 0.1 M
trisodium citrate (pH 6), and 4% Tacsimate (pH 5). Prior to data collection the
crystals were flash-cooled in a stream of liquid nitrogen at 100 K in a cryo-
protectant composed of reservoir solution supplemented with 35% PEG 3350.
X-ray diffraction data were recorded on a Quantum-315 CCD detector at the
MX2 beamline of the Australian Synchrotron. Data were integrated and
scaled using MOSFLM and SCALA from the CCP4 program suite (24).
Details of the data processing statistics are provided in Table I.
Structure determination and refinement
Structures were determined by molecular replacement as implemented in
PHASER (25). The search model used for the ternary complex was the
previously determined structure of the KIR3DL1-B57:01-LF9 ternary
complex (Brookhaven Protein Data Bank accession code 3VH8). Refine-
ment of the models was carried out in PHENIX (26) with iterative rounds
of manual building in COOT (27). Solvent molecules were added with
COOT and the structure validated with MOLPROBITY (28). The final re-
finement values are summarized in Table I.
Mutagenesis and transfection studies
3DL1 constructs with a 59 FLAG tag sequence (GACTACAAAGACGATG-
ACGACAAG) were cloned into a pEF6 vector. Specific nucleotide residues
were mutated using a QuikChange II site-directed mutagenesis kit (Stratagene)
with PAGE-purified primers and verified by direct sequencing. These con-
structs were introduced into HEK293T cells using FuGENE 6 transfection
reagent (Roche) according to the manufacturer’s instructions. Expression, lo-
calization, and correct folding of KIR proteins were monitored by flow
cytometry after staining with DX9, Z27, and anti-FLAG mAbs.
Tetramer staining
Fluorochrome-conjugated peptide-HLA class I tetramers were produced as
described previously (29). The specificities used in this study are detailed in
Table II. Cells were stained 48 h after transfection with optimal titers of
tetramer (0.2 mg with respect to the monomeric component in minimal re-
sidual volume) or anti-FLAG (clone M2; Sigma-Aldrich) mAb for 30 min at
4˚C. Ba/F3 cells stably expressing LILRB1 were used as a positive control for
tetramer binding. The LILRB1 receptor binds with equivalent affinity to a
broad range of HLA molecules, and this binding is dependent on the correct
folding of the HLA molecule and its association with b2-microglobulin (30),
but is independent of the presented peptide (31). Primary human PBMCs were
stained similarly with 0.5 mg tetramer, anti-CD3 (clone HIT3a; BD Bio-
sciences), and anti-CD56 (clone HCD56; BioLegend) mAbs. After RBC lysis
in hypotonic buffer, cells were washed and analyzed using an LSRFortessa
flow cytometer (BD Biosciences). For blocking experiments, cells were pre-
incubated with the indicated mAb (10 mg/ml) for 15 min at 4˚C.
Peptide loading and activation experiments
RMA-S cells transfected with HLA-B*5701 were incubated with indi-
vidual peptides at a concentration of 300 mM for 24 h at 26˚C. Stabili-
zation of HLA class I was measured by staining with W6/32 and anti-
HLA-B/C (B1.23.2) mAbs (eBioscience). Jurkat cells stably expressing
chimeric 3DL1-CD3z reporter constructs (8) were transiently transfected
with an NFAT-luciferase construct by electroporation, then stimulated with
peptide-loaded RMA-S cells for 18 h at 26˚C. Luciferase activity was
measured after cell lysis using a Dual-Glo luciferase assay (Promega).
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3DL1*001-CD3z and 3DL1*005-CD3z chimeric constructs were mu-
tated at position 283 as described above. Jurkat cells were transiently
transfected with these KIR constructs together with an NFAT-luciferase
reporter construct, then incubated for 18 h at 37˚C with parental 721.221
cells or specific HLA class I transfectants thereof (B*27:05, B*44:02, and
B*57:01). Luciferase activity was measured after cell lysis as described
above.
Results
Role of contact sites in the sensitivity of 3DL1*001
to C-terminal peptide variation
The recently published crystal structure of 3DL1*001 in complex
with HLA-B*57:01-LSSPVTKSF (LF9) highlighted an important
role for the P8 C-terminal residue of the bound peptide in the KIR–
HLA interaction. In line with the structural evidence, surface plasmon
resonance (SPR) experiments showed that variation at P8 affected
the affinity of the interaction between HLA-B*57:01 and 3DL1*001
(12). To extend this analysis, we examined the peptide sensitivity of
3DL1*001 expressed on human NK cells. Peripheral blood NK cells
from 3DL1*001+ donors were identified in flow cytometry experi-
ments by gating on CD32CD56+ lymphocytes. Tetrameric HLA-
B*57:01-LF9 complexes (tetramers) clearly stained a subset of these
NK cells, mirroring the percentage of 3DL1*001+ cells (Fig. 1A).
Moreover, tetramer staining could be blocked by incubation with the
3DL1-specific DX9 mAb (data not shown). We then examined the
interaction of 3DL1*001 with a series of HLA-B*57:01 tetramers in
which the P8 serine residue of LF9 was replaced in turn by alanine
(A8), glutamic acid (E8), phenylalanine (F8), histidine (H8), leucine
(L8), and arginine (R8) (Fig. 1B). The integrity of this tetramer panel
was confirmed by staining LILRB1-expressing Ba/F3 cell trans-
fectants (Fig. 1C). In contrast to the staining of LILRB1, 3DL1*001
binding was profoundly influenced by variation at the P8 residue.
Similar to the findings using SPR (12), the larger, bulky residues,
phenylalanine and histidine, were well tolerated. In contrast, the
charged residues, arginine and glutamic acid, significantly affected
KIR3DL1*001 binding; the glutamic acid substitution almost ab-
rogated tetramer staining. More surprisingly, the relatively com-
pact, nonpolar amino acids, alanine and leucine, also impaired
KIR3DL1*001 binding. Although the pattern and hierarchy of
interactions seen with the P8 tetramer panel is the same as that
measured by SPR (12), there are some differences in the sensitivity;
for example, whereas LF9-F8 and LF9-H8 show some reduction in
affinity by SPR, they bind as well as the wild-type peptide when
measured by flow cytometry. Based on SPR, the affinity for LF9-
R8 drops below that of LF9-F8 and LF9-H8, and we now detect
a dramatic loss in tetramer binding with this variant. This suggest
that, based on the levels of KIR expression on NK cells, binding as
detected by flow cytometry is relatively insensitive to small changes
Table I. Data collection and refinement statistics for 3DL1*001-HLA-
B*57:01.I80T-LF9 ternary complex
KIR3DL1*001-
HLA-B*57:01.I80T-LF9
Data collection statistics
Temperature (K) 100
X-ray source MX2 Australian synchrotron
Space group P1
Cell dimensions (A˚) a = 52.1, b = 61.5,
c = 66.4, a = 94.7˚,
b = 99.6˚, g = 109.1˚
Resolution (A˚) 40–2.00 (2.11–2.00)
Total no. observations 19,5349 (28,268)
No. unique observations 49,831 (7,177)
Multiplicity 3.9 (3.9)
Completeness (%) 98.2 (97.2)
1/sI 8.4 (2.8)
Rmerge
a 0.12 (0.66)
Refinement statistics
Nonhydrogen atoms
Protein 5,865
Water 493
Rfactor
b 0.198
Rfree
b 0.238
Root mean square
deviation from ideality
Bond lengths (A˚) 0.008
Bond angles (˚) 1.29
Ramachandran plot
Favored (%) 97.1
Allowed (%) 2.8
B-factors (A˚2)
Average main chain 37.9
Average side chain 41.8
Average water 41.4
aRmerge = +hkl +j |Ihkl,j 2 , Ihkl .|/+hkl +j Ihkl,j.
bRfactor = Shkl ||Fo| 2 |Fc||/Shkl |Fo| for all data excluding the 5% that comprised
the Rfree used for cross-validation.
Table II. List of tetramers used in this study
Name HLA Peptide Peptide Source
LF9 B*57:01 LSSPVTKSF Human
LF9 A8 B*57:01 LSSPVTKAF Modified from human
LF9 E8 B*57:01 LSSPVTKEF Modified from human
LF9 F8 B*57:01 LSSPVTKFF Modified from human
LF9 H8 B*57:01 LSSPVTKHF Modified from human
LF9 L8 B*57:01 LSSPVTKLF Modified from human
LF9 R8 B*57:01 LSSPVTKRF Modified from human
TW10 B*57:01 TSTLQEQIGW HIV
TW10 G9D B*57:01 TSTLQEQIDW HIV
KK10 B*27:05 KRWIILGLNK HIV
KF9 B*27:05 KRWGYSLNF Hepatitis B virus
KF9 N8H B*27:05 KRWGYSLHF Hepatitis B virus
AF9 B*27:05 ARMILMTHF Hepatitis C virus
RI9 B*27:05 RRFIIFLFI Hepatitis C virus
AY10 B*44:02 AENLWVTVYY HIV
RW8 A*24:02 RYPLTFGW HIV
RW8 A8 A*24:02 RYPLTFAW HIV
YL9 A*24:02 YLILEYAPL Human
VL9 A*24:02 VYAETKHFL Human
YI9 B*51:01 YPPPIQGVI HIV
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inKd, but tetramer binding decreases notably once the affinity drops
below a certain threshold.
Structural data strongly implicated the direct peptide contact res-
idue L166 and the water-mediated peptide contact residues Y200 and
E282 as determinants of 3DL1 peptide selectivity. To test these
structural predictions, we generated mutant 3DL1 proteins with
single residue substitutions at these sites and examined their ability
to bind HLA-B*57:01 tetramers refolded around LF9 or P8 var-
iants thereof. Wild-type 3DL1*001 transfectants displayed tetra-
mer binding preferences similar to those observed with primary
NK cells (Fig. 1D), although with reduced sensitivity to disruption
in the presence of unfavorable peptides, perhaps due to higher
expression levels. The L166 residue forms the only direct contact
with peptide in the HLA-B*57:01-LF9 complex, and variants are
found at this site across members of the KIR family, including
arginine in 3DS1 and valine in 3DL2. However, we found that the
introduction of alanine or valine at position 166, or indeed alanine
at position 165, only minimally affected 3DL1 peptide preferences
(Fig. 1D). Although subtle and reproducible differences were ob-
served, such as reduced binding to the LF9-F8 complex in the
presence of the M165A mutation and increased tolerance of the
LF9-L8 complex with L166A, these effects were minor.
Next, we addressed the role of Y200 and E282, which make
water-mediated contacts with peptide in the HLA-B*57:01-LF9
complex. The Y200 residue is central to the 3DL1–peptide-laden
HLA interaction and, as expected, the Y200A mutation substan-
tially reduced binding across the series of HLA-B*57:01 tetramers.
However, the LF9-F8 and LF9-H8 peptide variants partially res-
cued binding to this mutant (Fig. 1E). Although the Y200F sub-
stitution is more conservative, differing only by the absence of a
FIGURE 1. Amino acid residues at peptide
position P8 influence 3DL1*001 binding to HLA-
B*57:01. (A) Peripheral blood from a 3DL1*001+
donor was stained with HLA-B*57:01-LF9 tetra-
mer (0.5 mg) and mAbs as indicated. (B) Peripheral
blood NK cells were stained as in (A) with indi-
vidual HLA-B*57:01-LF9 tetramers incorporating
bound peptide substitutions at position P8. Data are
shown as the percentage of positive cells relative to
wild-type (WT) tetramer staining. (C) Ba/F3 cells
expressing LILRB1 were stained with the same
panel of tetramers. (D and E) HEK293 cells were
transfected with FLAG-tagged 3DL1*001, or sin-
gle amino acid variants thereof, and stained with
individual HLA-B*57:01-LF9 tetramers (0.2 mg
each) as in (B). Data are averaged from n = 2 (D)
or n = 3 (B, E) independent experiments. **p ,
0.01. Statistical significance relative to 3DL1*001
binding was assessed by ANOVA with a Tukey
multiple comparison posttest. Error bars represent
SE of the mean.
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hydroxyl group, this mutation resulted in a striking loss of toler-
ance for LF9-L8 and LF9-R8, whereas binding to other members
of the tetramer panel was well maintained. The E282A mutation
abolished interactions with HLA-B*57:01 across the entire panel
of peptide variants (data not shown). In contrast, the E282Q
mutation, which replaces the negatively charged glutamic acid
with the similarly sized neutral glutamine, dramatically reduced
HLA-B*57:01-LF9 tetramer binding. However, this was partially
reversed in the presence of LF9-F8 and LF9-H8 (Fig. 1E). As
predicted by the 3DL1*001-HLA-B*57:01-LF9 structure (12),
removal of the charge at position 282 in 3DL1 resulted in a greater
tolerance of LF9-E8. Similar to the Y200 substitutions, however,
tolerance of LF9-L8 and LF9-R8 was completely lost with E282Q.
Thus, we observed only minor effects due to substitutions at po-
sition 166, the point of direct peptide contact, but more dramatic
shifts in relative peptide preference when residues in the D1–D2
loop (200) or D2 domain (282) were targeted.
3DL1 residues and variants distant from the peptide contact
sites influence peptide preference
The ternary structure of the 3DL1*001-HLA-B*57:01-LF9 com-
plex suggested that peptide preference should not be regulated by
the D0 domain because its critical sites of interaction are distant
from the peptide. To confirm this, we examined the binding of
HLA-B*57:01-LF9 tetramers to mutant 3DL1 receptors bearing
D0 substitutions at HLA contact residues. Although certain mutations
of D0 residues involved in the HLA interaction (including positions 9,
11, and 29) did result in decreased HLA binding, we found that the
pattern and hierarchy of reactivity against our peptide panel mirrored
that of the wild-type KIR (data not shown). 3DL1*015 differs from
*001 only in the D0 domain, with three amino acid differences (M2V,
I47V, I54L). Despite the sequence divergence in D0, *015 revealed
a strikingly similar binding profile to that of *001, both in terms of
peptide selectivity and the role of D1/D2 amino acids (including L166,
Y200, and E282) in this pattern of reactivity (data not shown). Col-
lectively, these data suggest that D0 contacts and polymorphisms
within the D0 domain play little or no role in peptide permissiveness.
In addition to KIR residues involved in peptide contacts, our
systematic analysis revealed that substitutions at other contact sites,
including 199, 230, and 279, also modified 3DL1 peptide reactivity
(Fig. 2A, 2B). The P199A mutation in the D1–D2 loop resulted in
a minor decrease in overall HLA-B*57:01 recognition and also
specifically reduced binding to the LF9-L8 tetramer (Fig. 2A). The
D230A mutation resulted in a profound loss of reactivity for all
but the three strongest interactions (LF9, LF9-F8, and LF9-H8).
The S279A mutation, in contrast, resulted in a unique pattern of
reactivity, with a very strong preference for the LF9-R8 tetramer.
These changes in peptide specificity could be due either to direct
effects on peptide interactions via alteration of the binding inter-
face or indirect effects transmitted to other KIR residues.
Very few of the sites of 3DL1 allotypic variation map to the
residues involved in the HLA-B*57:01 interaction, and all of the
inhibitory 3DL1 variants (barring the unique *054) are identical at
the residues involved in direct or water-mediated contacts with
peptide (L166, Y200, and E282) (12). To explore how 3DL1 al-
lotypic variation influences the repertoire of permissive peptides,
we examined the ability of a range of 3DL1 allotypes to interact
with our tetramer panel. Across a large panel of variants, we saw
little effect on peptide preference (four common allotypes are
shown in Fig. 2C, a full list of allotypes tested is shown in
Supplemental Table I), with the exception of *005. This allotype
showed a subtle shift in reactivity, with a slight reduction in LF9-
R8 and an increase in LF9-L8 reactivity, such that both of these
variants were equally well tolerated. 3DL1*005 differs from the
other tested allotypes at position 283, which is located at the D1–
D2 interface (Fig. 2B), carrying a leucine rather than a tryptophan
(Fig. 2D). Because this residue is positioned directly beside the
central E282, we examined the potential of L283 to influence
peptide interactions. In two 3DL1 allotypes, *001 and *015, the
single W283L mutation resulted in the *005-like phenotype with
equivalent recognition of LF9-L8 and LF9-R8 (Fig. 2E). The re-
ciprocal substitution, *005 L283W, resulted in a clear preference
for LF9-R8 over LF9-L8, as observed with the *001 and *015
allotypes. In the case of L8, it is clear that in the context of *005,
L8 binding is greater than that seen with *001 and *015, and that
this difference is lost with the L283 mutation. In contrast, intro-
duction of 283L into either *001 or *015 does not significantly
increase L8 binding. This result suggests that additional changes
in *005 (such as P182S) contribute to selective binding to peptide
variants. Collectively, these data show that position 283 can im-
pact the peptide sensitivity of 3DL1.
Allotypic variation at position 283 in the D2 domain influences
HIV-associated peptide variant recognition
Based on our data with the LF9 peptide variants, we next examined
whether these KIR contacts and polymorphisms played a role in the
recognition of other peptides, specifically those presented during
infection. Accordingly, we examined recognition of the HLA-
B*57/B*58–restricted HIV-1 p24 Gag epitope TW10. The HLA-
driven evolution of HIV-derived peptide sequences, including TW10,
has been well documented (32). Described variants of TW10 in-
clude G9D, a residue predicted to alter 3DL1 interactions. In
agreement with an earlier study (33), we found that this substitution
did indeed result in a loss of 3DL1*001 binding (data not shown).
To establish the functional consequences of altered peptide recog-
nition in this system, we examined the effect of G9D substitution on
3DL1 triggering. A chimeric fusion protein consisting of 3DL1*001
fused to CD3z was expressed in Jurkat T cells and activation was
measured with a luciferase reporter construct. Transfectants were then
cultured alone or with the TAP-deficient RMA-S cell line expressing
HLA-B*57:01 pulsed with either the TW10 or TW10-D9 peptide.
Functional 3DL1*001 engagement was detected with TW10-pulsed
cells, but not with TW10-D9–pulsed cells (Fig. 3A), despite equivalent
stabilization of HLA-B*57:01 on the cell surface (data not shown).
Thus, peptide discrimination toward the C terminus influences KIR
engagement.
To uncover the mechanism responsible for the lack of HLA-
B*57:01-TW10-D9 recognition, we conducted tetramer binding
experiments with a series of 3DL1 mutants. We found that the loss
of TW10-D9 tetramer binding was likely due to charge repulsion
between the aspartic acid at P9 and E282 in the D2 domain of the
KIR. Consistent with this, the E282Q substitution restored bind-
ing to levels observed with 3DL1*001 and the TW10 peptide
(Fig. 3B). Indeed, in the presence of the E282Q mutation, the G9D
peptide was vastly preferred over wild-type. These data indicate
that the negative charge at position 282 plays a dominant role in
discrimination of this variant epitope.
Although these findings shed light on the molecular rules that
govern peptide selectivity, we wanted to address the role of nat-
urally occurring variation given that position 282 is invariant across
all 3DL1 allotypes. In light of the distinct peptide reactivity pattern
observed with *005 in the context of LF9 variants (Fig. 2), we
examined the ability of 3DL1 allotypes to bind TW10 and TW10-
D9. Increased binding of the HLA-B*57:01-TW10-D9 tetramer
by *005 relative to the *001 and *015 allotypes was observed on
transfected cell lines (Fig. 3C) and primary human NK cells
(Fig. 3D). Similar to our observations with the LF9 peptide panel,
this pattern was not seen with *007, which is classified as a low
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allotype together with *005. However, *053, a poorly expressed
allotype that contains a leucine at position 283 similar to *005,
also exhibited substantial recognition of the G9D variant (Fig. 3C).
These findings suggested that the observed pattern of peptide re-
activity was not related to the low classification of these 3DL1
allotypes. Because we had demonstrated earlier that residue 283
was involved in LF9-L8/R8 discrimination, we tested TW10-D9
tetramer binding by *001, *015, and *005 allotypes in which po-
sition 283 was substituted with either tryptophan or leucine. The
W283L mutation in both *001 and *015 resulted in a significant
increase in TW10-D9 tetramer binding. Conversely, the L283W
mutation in *005 significantly reduced TW10-D9 tetramer binding
(Fig. 3E). Therefore, the presence of leucine at position 283 is spe-
cifically responsible for the recognition of HLA-B*57:01-TW10-D9.
The importance of this residue potentially relates to modulatory
effects on the nearby E282, which is responsible for the diminished
reactivity with TW10-D9 due to charge repulsion.
Position 283 controls 3DL1 allotypic discrimination between
Bw4 80I and 80T
Amajor division in HLA-Bw4 allotypes is based on the amino acid
present at the dimorphic position 80 (isoleucine or threonine), and
we have shown that the I80T mutation in the HLA-B*57:01-LF9
complex results in decreased binding to KIR3DL1*001 (12). This
dichotomy within Bw4 molecules is of much interest owing to the
resulting functional and clinical consequences reported by genetic
studies (13, 16). To elucidate any unique features associated with
the 3DL1–Bw4 80T interaction, we determined the structure of
3DL1*001 in complex with HLA-B*57:01 containing the I80T
mutation to 2.0 A˚ resolution (Fig. 4A, Table I). The structures of
the I80T mutant and the native complexes were very similar with
a root mean square deviation over all Ca positions of 0.3 A˚.
Accordingly, the contacts between 3DL1 and the HLA were
conserved with the exception of position 80. In the native ternary
complex, the isoleucine at position 80 formed a network of van
der Waals contacts via the Cd1 methyl group of the side chain
(Fig. 4A). This network involved contacts to the carboxyl terminus
of the peptide, the side chains of E76 and N77 (HLA), and L166
(KIR). These direct contacts were lost with the mutation to thre-
onine at position 80. However, the network of contacts to the Cd1
group of I80 was partially restored in the T80 structure by an
ordered water molecule (Fig. 4A). This water molecule formed
bridging H-bonds between the Og-hydroxyl group of T80 and the
carboxyl terminus and S8 of the peptide as well as to N77 (HLA).
Furthermore, the water molecule forms van der Waals contacts
with L166 (KIR), coincident with a 0.5 A˚ shift in the side chain of
FIGURE 2. Allotypic variation influences peptide preference. (A, C, and E) HEK293 cells were transfected with FLAG-tagged 3DL1*001, other 3DL1
allotypes, or mutants thereof and stained with individual HLA-B*57:01-LF9 tetramers (0.2 mg each) as indicated. Data are averaged from at least n = 3
independent experiments. *p , 0.05, **p , 0.01. Statistical significance relative to 3DL1*001 binding was assessed by ANOVA with a Tukey multiple
comparison posttest. Error bars represent SEM. (B) The structure of 3DL1*001-HLA-B*57:01-LF9 with residues of interest highlighted. (D) Alignment of
the 3DL1 allotypes used in this study. Variable residues are numbered and grouped by protein domain in the mature full-length protein.
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L166. The replacement of direct contacts at the binding interface
with a network of water-mediated contacts will subtly affect the
dynamics of the interaction and likely accounts for the reduction
in affinity for Bw4 80T allotypes observed with 3DL1*001.
Next, we examined the role of peptide in the context of HLA
Bw4 80T using a panel of three HLA-B*27:05 tetramers (Table II).
In addition to the HIV-derived KK10 peptide, we also examined
the binding to the HBV-derived KF9 (KRWGYSLNF) epitope and
its variant KF9 N8H (KRWGYSLHF). In contrast to HLA-
B*57:01 tetramer binding, mutation of 3DL1 residues M165 or
L166 generally decreased the HLA-B*27:05 interaction; the ex-
ception was HLA-B*27:05-KK10, which displayed increased
binding in the presence of L166A (Fig. 4B). The role of A167 also
appeared to be peptide-dependent because the A167G mutant
showed decreased binding to both the KK10 and KF9 tetramers,
but not to the KF9-H8 variant. These findings uncover a role for
the 165–167 loop in controlling HLA–Bw4 80T interactions that
is dependent on the sequence of the presented peptide and distinct
from that seen with HLA-Bw4 80I. Thus, variation in both the
peptide sequence and the Bw4 motif alters the contribution of
individual KIR contact residues to the overall stability of the
KIR–HLA complex.
The interaction of certain 3DL1 allotypes showed a strong
preference for Bw4 80I over Bw4 80T interactions, whereas others
seemed to interact equally well with both classes of Bw4 molecules
(Fig. 5A). Despite some suggestions from genetic association
studies, we found that this discriminatory capacity did not seg-
regate well with low and high KIR allotypes. For example, *007
showed a pattern more similar to the high allotypes *001 and *015
than to its fellow low allotype *005. The binding of *053 (a low
allotype) to both Bw4 80I and 80T was poor and nonpreferential
(Fig. 5A). Guided by this and by our peptide interaction results
(Figs. 2, 3), we examined the role of residue 283 in the discrim-
ination between HLA Bw4 subgroups. Position 283 was com-
pletely responsible for the preferential binding of Bw4 80I over
Bw4 80T in W283 allotypes. The W283L mutation in both *001
and *015 substantially increased their interactions with all mem-
bers of a panel of Bw4 80T tetramers (Fig. 5B). Conversely, *005
FIGURE 3. Position 283 in the D2 domain of 3DL1 allotypes dictates HIV-derived epitope variant recognition. (A) 3DL1*001-CD3z reporter Jurkat cells
were stimulated with RMA-S HLA-B*57:01–expressing cells loaded with TW10 or TW10-D9 peptides for 18 h at 26˚C. The cells were lysed and lu-
ciferase activity was measured. (B and C) HEK293 cells were transfected with FLAG-tagged 3DL1*001, other 3DL1 allotypes, or mutants thereof and
stained with individual tetramers (0.2 mg each) as indicated. (D) Peripheral blood from 3DL1-genotyped donors was stained with individual tetramers (0.5
mg each) as indicated. Data are shown as percentage positive cells relative to those staining with the HLA-B*57:01-TW10 tetramer. (E) HEK293 cells were
transfected with FLAG-tagged 3DL1 allotypes and mutants thereof with reverted amino acid substitutions at position 283, then stained with individual
tetramers (0.2 mg each) as indicated. Data are averaged from at least n = 3 independent experiments. *p, 0.05, **p, 0.01. Statistical significance relative
to KIR3DL1*001 binding was assessed by ANOVA with a Tukey multiple comparison posttest. Error bars represent SEM.
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showed much reduced recognition of Bw4 80T in the presence of
the L283W mutation. In contrast, no consistent effect of substi-
tution at position 283 was observed on Bw4 80I tetramer binding
(data not shown). To confirm the role of position 80, we used HLA-
B*57:01-LF9 tetramers containing the I80T mutation. As expected,
*001 (and *015) showed decreased binding to HLA-B*57:01 I80T
tetramers, whereas *005 showed no ability to discriminate between
Bw4 80I and 80T. This effect could be reversed for all three allotypes
by switching residues at KIR position 283 (Fig. 5C). Thus, the bifur-
cation of 3DL1 variants based on this D2 residue represents the emer-
gence in humans of an allotype lineage (*005-like) that exhibits both
broader peptide recognition and broader HLA Bw4 recognition.
FIGURE 4. Interaction of 3DL1*001 with HLA-
Bw4 80T allotypes strongly resembles the 3DL1/HLA-
Bw4 80I interaction and is sensitive to peptide. (A) The
crystal structure of HLA-B*57:01.I80T-LF9 in com-
plex with 3DL1*001 (right panel) was solved and
compared with the 3DL1*001-HLA-B*57:01-LF9
structure (left panel). The HLA and KIR are colored
green and blue, respectively. Dashed lines represent
contacts. (B) HEK293 cells were transfected with
FLAG-tagged 3DL1*001 or mutants thereof, then
stained with individual HLA-B*27:05 tetramers (0.2 mg
each) as indicated.
FIGURE 5. Position 283 controls 3DL1 allotypic discrimination between Bw4 80I and 80T. (A and B) HEK293 cells were transfected with FLAG-tagged
3DL1 allotypes or mutants thereof with reverted amino acid substitutions at position 283, then stained with individual Bw4 80T tetramers (0.2 mg each) as
indicated. (C) 3DL1 allotypes or position 283 mutants were stained with HLA-B*57:01.I80T-LF9 tetramer (0.2 mg). Data are shown as percentage binding
relative to the wild-type HLA-B*57:01-LF9 tetramer. Binding to LILRB1-expressing cells is shown as a control. Data are averaged from at least n = 3
independent experiments. *p , 0.05, **p , 0.01. Statistical significance was assessed by ANOVAwith a Tukey multiple comparison posttest. Error bars
represent SEM.
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Discussion
In this study, we describe a dichotomy within the 3DL1 family of
KIRs based on position 283 in the D2 domain that confers distinct
patterns of HLA reactivity and peptide permissiveness. Two groups
of allotypes, corresponding to the *015-like and *005-like genetic
lineages, are delineated by these data. The *005-like lineage, in-
corporating leucine at position 283, shows robust recognition of
both Bw4 80T and 80I HLA allotypes and broader peptide toler-
ance than the *015-like lineage, which incorporates tryptophan at
the corresponding site. Thus, we define a molecular signature that
underlies a functional bifurcation of 3DL1 allotypes, thereby pro-
viding the basis for a simple typing assay that would be readily ap-
plicable to clinical studies.
For both the LF9-E8 and TW10-D9 peptides, our findings suggest
that charged residues, in particular negatively charged residues,
disturb the interaction with 3DL1. These data are in line with the
findings of Stewart-Jones et al. (20), who found that glutamic acid
at P8 was not tolerated in the context of HLA-B*27:05. Our data
suggest that this reflects the role of KIR residue E282 in the peptide
interaction. This negatively charged residue clearly restricts toler-
ance of negatively charged C-terminal peptide residues. However,
perturbation of E282 can result in unique peptide specificity pro-
files, suggesting that its role in peptide discrimination is not simply
due to the potential for electrostatic clashes. During immune-
mediated evolution of HIV epitopes within a particular host, the
acquisition of negatively charged C-terminal residues may inter-
fere with 3DL1*001 recognition and result in NK cell activation,
to the detriment of the virus. Our data suggest that L283 allotypes,
including *005, are less sensitive to these peptide substitutions,
and these donors are more likely to maintain NK cell inhibition.
Accordingly, we would predict commensurate increases in the fre-
quency of such HIV-derived epitope mutations.
The dimorphic residue at position 283 has a dramatic influence on
both peptide and HLA interactions. This could reflect either a direct
role in the peptide-laden HLA interaction or transmitted effects im-
pinging on neighboring or distant residues. The increased recogni-
tion of the TW10-D9 peptide observed with L283 allotypes is more
parsimoniously explained by an effect on the neighboring E282
residue, which is the primary block to TW10-D9 recognition. This
same change (W283L) also results in equivalent recognition of Bw4
80I and 80T molecules. In this case, it is possible that the positioning
or availability of E282 results in increased affinity for Bw4 80T
molecules. However, structural analysis reveals that the side chains of
these two residues (282 and 283) are not in contact. Thus, it is perhaps
more likely that position 283, located at the interface between the D1
and D2 domains, influences the relative positioning of these two
domains. The switch between the large, bulky, hydrophobic tryp-
tophan and the smaller leucine residuewould be expected to influence
the hinge angle between these domains and thereby influence ligand
interactions. Indeed, the differential interaction of 2DL2 and 2DL3
with HLA-C2 allotypes is thought to result from an influence of
polymorphic residues on the interdomain hinge angle (34, 35). A
role for position 283 in 3DL1 protein conformation has also been
suggested by Parham and colleagues (36) on the grounds that this
amino acid results in differential Ab affinity.
The division of 3DL1 allotypes based on a dichotomy at position
283 defines two separate lineages with distinct peptide and Bw4
80T epitope recognition properties. In all other KIR molecules,
including 3DS1, 3DL2, 2D, and nonhuman primate KIRs, the
position equivalent to 283 is represented by tryptophan. Genetic
analysis of the 3DL1 lineages suggests that both L283 and W283
are ancient and actively maintained in human populations, albeit
with some exceptions (4). The emergence and maintenance of
L283 implies a functional advantage at the population level to the
presence of both 3DL1 specificities. In light of the known co-
evolution of HLA and KIR (37), it is interesting to speculate that
the *005-like lineage might have arisen in populations with a high
prevalence of Bw4 80T. In these populations, W283 3DL1 allo-
types would be expected to lead to poor recognition, and the
emergence of L283 would have generated a 3DL1 specificity
capable of robust interactions with the dominant HLA allotypes.
In a functional analysis of the interaction of KIR3DL1 allotypes
with a broad array of HLA-Bw4–expressing target cells, Foley et al.
(38) did not detect any discrimination between 80I and 80T allo-
types using 3DL1*001, *005, *015, and *053 allotypes. Based on
our binding data, we would have predicted that although *005 and
*053 (L283) would not discriminate, both *001 and *015 would
show a preference for 80I Bw4 allotypes. Indeed, other functional
assays have revealed a preference for 80I by some KIR3DL1
allotypes, including *001 (8, 13), and epidemiological evidence
from HIV infection supports a functional role for the Bw4 80I/80T
dichotomy in KIR interactions that ultimately influence disease
outcome. Taken together, these findings suggest that the differences
in binding affinities that we describe in this study do have func-
tional consequences. Although these differences may be masked in
some experimental set-ups (due, for example, to high levels of li-
gand expression, expression of additions receptors, and other fac-
tors), there is an abundance of data that suggest the groupings we
define in the present study are functionally relevant and should be
considered in the clinical assessment of KIR–HLA interactions.
The most common functional allotypewithin the L283 grouping is
*005. This allotype is found at a frequency of ∼10–40%, although it
is quite rare in some populations (39). Other L283 allotypes include
*004 (which is not expressed at the cell surface), *019, *040, *041,
*042, and *053; with the exception of *004, however, these are not
found at high frequencies in human populations. Thus, the dominant
L283 allotype (*005) is also a low 3DL1 variant. The functional
consequences of low expression are not clear. In an in vitro assay,
NK cells expressing the high *002 or the low *005 receptors were
equally inhibited by a target cell line expressing the Bw4 80I al-
lotype B*58:01 (40). It is possible that during their maturation
process, NK cells are tuned to the level of inhibitory signal received.
In this scenario, NK cells expressing low levels of 3DL1 are max-
imally inhibited by a lower signal threshold than those expressing
higher levels of 3DL1. This is similar to the education model, in
which those NK cells that do not receive any inhibitory signals are
hypofunctional, an effect that has been shown to exist across a
spectrum of reactivities according to the rheostat model (41, 42).
Genetic association studies that have classified 3DL1 receptors
into high and low on the basis of expression, and have found dif-
ferential interactions with Bw4 80Tallotypes, may therefore simply
reflect a molecular division that hinges on the residue present at
position 283. As such, low allotypes would show better epistatic
interactions with Bw4 80Tallotypes solely due to the dominant role
of *005 (a L283 allotype) in Bw4 80T recognition. The next most
common low allotype is *007, which incorporates tryptophan at
position 283. By our predictions, it should segregate with high
allotypes due to the common residue at position 283.
In summary, we have described a lineage-defining dimorphism
in 3DL1 allotypes that controls both HLA reactivity and peptide
specificity. The categorization of KIR-HLA combinations into
functional groups is of significant clinical interest in multiple
settings. At present, the classification of KIR allotypes into high or
low expression requires complete 3DL1 subtyping and is based
purely on phenotypic evaluation because there are no common
molecular features that segregate with all low allotypes. Some of
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the amino acids responsible for low cell surface expression have been
identified for some allotypes (e.g., *005, *028) (11, 43), but these are
not shared with other low allotypes (e.g., *007). In contrast, the
classification of allotypes based on the amino acid present at posi-
tion 283 is straightforward and definitive, and we are currently
developing a simplistic typing system that would provide quanti-
tative information on the possession of 3DS1, 3DL1*004, 3DL1
L283, and 3DL1 W283 allotypes. This assay will enable direct
measurement of the causative variant in the functional bifurcation
of 3DL1 allotypes and should prove amenable to rapid and cost-
effective clinical implementation.
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